Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
about
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.Pembrolizumab use for the treatment of advanced melanoma.Part I: Checkpoint inhibitors in cancer therapy.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
P2860
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@en
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@nl
type
label
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@en
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@nl
prefLabel
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@en
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab.
@nl
P2093
P2860
P50
P356
P1433
P1476
Pembrolizumab in a BRAF-mutant ...... adverse event with ipilimumab
@en
P2093
Aleix Prat
Iván Victoria
Lydia Gaba
Mónica Tosca
P2860
P304
P356
10.2217/IMT-2015-0025
P577
2016-04-26T00:00:00Z